Biobot Surgical, a Singapore-based medical technology company developing robotic-assisted systems for prostate cancer diagnosis and treatment, has secured S$20 million in its latest financing round led by ClavystBio in partnership with ZIG Ventures.

总部位于新加坡的医疗科技公司 Biobot Surgical 致力于开发用于前列腺癌诊断和治疗的机器人辅助系统，该公司在由 ClavystBio 与 ZIG Ventures 联合领投的最新一轮融资中成功筹集 2000 万新加坡元。

The funding will accelerate the adoption of its Mona Lisa platform – which integrates robotic needle guidance and MRI-ultrasound image fusion for targeted prostate biopsy and focal ablation workflows – across its international markets.

这笔资金将加速其Mona Lisa平台在国际市场的推广与应用——该平台整合了机器人针头引导和MRI-超声图像融合技术，用于靶向前列腺活检和局部消融工作流程。

It will also help to establish a focused US beachhead strategy, expand its clinical and economic evidence base, and strengthen the commercial capabilities required for its next phase of growth.

这将有助于建立聚焦的美国市场切入战略，扩大其临床和经济学证据基础，并加强下一阶段增长所需的商业化能力。

Prostate cancer is one of the most common cancers affecting men worldwide, with more than 1.4 million new cases diagnosed annually.

前列腺癌是全球男性中最常见的癌症之一，每年新诊断病例超过140万例。

Biobot has deployed more than 80 systems globally and has supported more than 30,000 patients, with adoption across leading centres in Europe and APAC. The company’s evidence base includes more than 50 real-world clinical publications, supporting its role in targeted transperineal prostate biopsy and precision needle placement..

Biobot已在全球部署了80多个系统，支持了超过30,000名患者，并在欧洲和亚太地区的主要医疗中心得到广泛应用。该公司的证据基础包括50多篇真实世界临床出版物，支持其在靶向经会阴前列腺活检和精准穿刺针定位中的作用。

By allowing procedures to move from hospital operating rooms into ambulatory surgery centers and, over time, in-office settings, Mona Lisa helps providers improve access, streamline workflow and strengthen procedure economics.

通过使手术从医院手术室转移到门诊手术中心，并随着时间的推移进一步转移到诊所内环境，Mona Lisa 帮助医疗服务提供者提高可及性、简化工作流程并增强手术的经济效益。

As part of its US commercialisation strategy, Biobot will work with Fogarty Innovation to define priority clinical segments, expand engagements with clinicians and accelerate adoption.

作为其美国商业化战略的一部分，Biobot 将与 Fogarty Innovation 合作，确定优先临床领域，扩大与临床医生的互动，并加速产品采用。